Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113212 | 0.87 | CYP4F2 (0.76) | CYP4F2CYP4A11HPGDALDH1A1MAPT | |
| SCHEMBL28449977 | 0.83 | MAPT (0.60) | CYP4F2CYP4A11ALDH1A1MAPTKMT2A | |
| SCHEMBL12028692 | 0.82 | SLC7A5 (0.57) | CYP4F2CYP4A11HPGDALDH1A1MAPT | |
| SCHEMBL2286242 | 0.80 | CYP4F2 (0.61) | CYP4F2CYP4A11HPGDALDH1A1MAPT | |
| SCHEMBL4765884 | 0.79 | CYP4F2 (0.56) | CYP4F2CYP4A11HPGDALDH1A1MAPT | |
| SCHEMBL4765888 | 0.79 | CYP4F2 (0.56) | CYP4F2CYP4A11HPGDALDH1A1MAPT | |
| SCHEMBL16090748 | 0.79 | CYP4F2 (0.56) | CYP4F2CYP4A11HPGDALDH1A1MAPT | |
| SCHEMBL11076678 | 0.79 | POLB (0.48) | ALDH1A1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL10065854 | 0.79 | CA2 (0.56) | HPGDALDH1A1MAPTKMT2AGAA | |
| SCHEMBL112488 | 0.79 | CYP4F2 (0.66) | CYP4F2CYP4A11ALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-7569602-B2 | Furan derivatives as EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-6992193-B2 | Sulfonylamino phenylacetamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-01-31 | — | — | US | disclosed |
| WO-2005004796-A2 | SULFONYLAMINO PHENYLACETAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040254156-A1 | Sulfonylamino phenylacetamide derivatives and methods of their use | CALIXA THERAPEUTICS, INC. | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254156-A1 | Sulfonylamino phenylacetamide derivatives and methods of their use | CYP2E1, CYP2D6, CYP3A43 | CYP4F2 44/4885CYP4A11 49/4885HPGD 528/4885 |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER3, NR4A3 | CYP4F2 1009/4885CYP4A11 395/4885HPGD 1200/4885 |
| US-20070135503-A1 | Furan derivatives as ep4 receptor antagonists | PTGER4, PTGER3, NR4A3 | CYP4F2 602/4885CYP4A11 384/4885HPGD 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.